Hormonal Therapy Articles & Analysis: Older
37 news found
Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. Such APIs come in a wide range of types: chemotherapeutic, targeted, immunotherapeutic, hormone therapeutic. The APIs in chemotherapy work by interfering with the cell division mechanism to suppress cancer cell growth. In ...
CD Formulation's extensive range of APIs can be classified into amino acid series, antibacterial, anti-inflammatory and antiviral series, cardiovascular series, hormone series and other APIs. All these APIs are essential for the development of effective drugs to meet various medical needs. ...
“Our innovative drug delivery solutions are ideal for a wide range of pharmaceutical and biotech applications, such as gene therapy, immunotherapy, hormonal therapy, anti-infectives, and vaccines,” said the Marketing Chief of CD Formulation. ...
” The approval is based on the positive results from the Phase III ARASENS trial, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ...
ByBayer AG
European Commission granted approval of Nubeqa (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) Approval is based on Phase III ARASENS trial data The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus ...
ByBayer AG
The MHLW approval is based on the positive results from the Phase III ARASENS trial, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ...
ByBayer AG
Upon relapse, when the disease will metastasize or spread, or if the disease is newly diagnosed, but has already spread, the disease is hormone-sensitive and androgen deprivation therapy (ADT) is the cornerstone of treatment. Current treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC) include ...
ByBayer AG
Upon relapse, when the disease will metastasize or spread, or if the disease is newly diagnosed, but has already spread, the disease is hormone-sensitive and androgen deprivation therapy (ADT) is the cornerstone of treatment. Current treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC) include ...
ByBayer AG
While around 16 million women each in the United States and Europe suffer from vasomotor symptoms, there are still limited treatment options available. Hormone therapy, the current standard of care, is not an option for many women due to contraindications or personal preference. ...
ByBayer AG
This collaboration represents a shared commitment to maximizing the potential of novel combination therapies to improve outcomes for people living with breast cancer.” “This new clinical collaboration with Carrick Therapeutics is yet another step we are making to develop elacestrant in an extensive way to address unmet needs of patients resistant to CDK4/6 ...
It reveals patients' response to targeted therapy, immunotherapy, hormonal therapy, chemotherapy and oncology clinical trials - screening for cancer gene mutations in the DNA AND RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (TUMOUR MUTATIONAL BURDEN, HOMOLOGOUS RECOMBINATION DEFICIENCY AND MICROSATELLITE INSTABILITY ...
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
New results from the Phase III ARASENS trial evaluating quality of life (QoL) and patient-relevant endpoints for darolutamide plus androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) show that, in addition to extending overall survival (OS), darolutamide has a strong tolerability profile and ...
ByBayer AG
Last year, Gesynta Pharma initiated an extensive evaluation of the drug candidate in a preclinical disease model of endometriosis - a painful inflammatory disease affecting millions of women, where the need for effective non-hormonal therapies is substantial. Scientific literature suggests a benefit of inhibiting mPGES-1 to relieve endometriosis symptoms for ...
Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results of the Phase III ARASENS trial that demonstrated darolutamide plus ...
ByBayer AG
Waisman is a leading contract manufacturing organization (CMO) with experience in the manufacturing of cellular therapies for clinical trials. Under the terms of the agreement, Waisman will be responsible for good manufacturing practice (GMP) manufacturing of Bria-Pros™ for anticipated use in clinical studies. ...
The latest research builds on the 2019 FAKTION trial based on the use of capivasertib, an investigational breast cancer drug developed by AstraZeneca that blocks the activity of a protein called AKT that has been shown to contribute to resistance to hormone therapy. The 2019 research found that, by combining capivasertib with a standard hormonal ...
About the ARASENS Trial The ARASENS trial is the only randomized, Phase III, multi-center, double-blind trial which was prospectively designed to compare the use of a second-generation oral androgen receptor inhibitor (ARi) plus androgen deprivation therapy (ADT) and docetaxel to ADT plus docetaxel (a guideline recommended standard-of-care) in metastatic ...
ByBayer AG
For 135 “favorable” patients treated with Cesium-131 implant alone (excluding 12 patients who were treated with external beam radiation therapy and Cesium-131 implant), the outcome was 98.1%. Intermediate-risk prostate cancer can be classified as “favorable” (FIR) or “unfavorable” (UIR). ...
ARASENS demonstrated that the addition of darolutamide, an androgen receptor inhibitor, significantly increased overall survival for patients receiving standard androgen deprivation therapy and docetaxel as initial treatment for metastatic hormone-sensitive prostate cancer. ...
ByBayer AG